SynthesisMedicine2026
The effects of steroid treatment on osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are often treated with steroids to alleviate their symptoms. Prolonged corticosteroid use can lead to decreased bone mineral density (BMD). However, the impact of steroid treatment regimens on BMD in patients with IBD is not fully understood. This study aimed to investigate the effects of corticosteroid therapy on BMD in IBD patients.
methodsA predetermined protocol registered in the PROSPERO registry under reference CRD42024518193. We searched the MEDLINE, EMBASE, Web of Science, and Cochrane Library databases to identify studies reporting the BMD of IBD before April 2024. Studies were evaluated using the Newcastle-Ottawa Scale. Sensitivity analyses and Begg's asymmetric test were used to detect bias.
resultsFollowing screening and evaluation, a meta-analysis of steroid odds ratios (ORs) of BMD in IBD was conducted based on 18 selected studies, with a total of 27,716 participants. The abnormal BMD in IBD was with an odds ratio (OR) of 2.31 (95% confidence interval [CI]: 1.19-4.48), osteoporosis in IBD with OR of 1.62 (95% CI: 1.02-2.58), osteoporosis in CD with an OR of 1.21 (95% CI: 0.85-1.73), osteoporosis in UC with an OR of 1.00 (95% CI: 0.87-1.16), abnormal BMD in CD with OR of 1.02 (95% CI: 0.99-1.06), abnormal BMD in UC with OR of 1.44 (95% CI: 1.07-1.95).
conclusionPatients diagnosed with IBD who received glucocorticoid therapy did not show a significant increase in osteoporosis (BMD T ≤ -2.5), especially in the UC group, despite having a higher tendency for bone loss (BMD T ≤ -1). The osteoporosis observed in IBD patients may require further comprehensive exploration and clarification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.